Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) To Host Official Opening Ceremony Of Headquarters


Leading T-cell therapy firm Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) has disclosed that it will be hosting an official opening ceremony for its new headquarters in the United Kingdom located in Oxfordshire. More than 400 guests are expected to attend and this includes employees as well representatives from government, academia and the business world. A commemorative plaque will be unveiled by University of Oxford’s Regius Professor of Medicine, Prof. Sir John Bell.

“We are proud to celebrate the official opening of this exciting new building, which provides best-in-class laboratories to support the activity of our highly skilled research and development teams and the advancement of our research programs,” said Adaptimmune’s chief executive officer, James Noble.

Entire corporate team

The new headquarters of Adaptimmune has a space measuring 67,000 square feet and this comprises office and laboratory space. Adaptimmune’s entire corporate team as well as the employees in the research and development unit will be house there. In the United States Adaptimmune Therapeutics also recently constructed new headquarters in Philadelphia, Pennsylvania.

The leading T-cell therapy firm was founded in 2008 when it started with three people who were working in a tiny laboratory located on Milton Park. Currently the number of employees at the pharmaceutical firm has grown to over 350 people located in both the United States and the United Kingdom.

Trials in progress

The announcement concerning the opening ceremony of the new corporate headquarters comes a few days after Adaptimmune Therapeutics disclosed that it would be presenting at this year’s SITC annual meeting which will be held between November 8 and November 12 two trials in progress posted. This will be at the National Harbor’s Gaylord National Hotel & Convention Center in Maryland, United States. The presentation will focus on Adaptimmune’s ongoing study of MAGE-A4 multi-tumors in urothelial, gastric, melanoma, ovarian, head and neck, gastric, esophageal, and NSCLC cancers.

Additionally during the same event Adaptimmune Therapeutics will also host an investors’ dinner in which representatives of the leadership team of the pharmaceutical firm will be available. The University of Texas MD Anderson Cancer Center’s Dr. David Hong, a key opinion leader, will also be there.

On Tuesday shares of Adaptimmune Therapeutics fell by 3.20% to close the day at $8.17.


Please enter your comment!
Please enter your name here